BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 1614274)

  • 1. Reversible, amine--selective effects of acute and chronic brofaromine treatment in the rat.
    Dyck LE; Boulton AA
    Life Sci; 1992; 51(1):59-66. PubMed ID: 1614274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of monoamine oxidase inhibitors on some arylalkylamines in rate striatum.
    Philips SR; Boulton AA
    J Neurochem; 1979 Jul; 33(1):159-67. PubMed ID: 572413
    [No Abstract]   [Full Text] [Related]  

  • 3. Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.
    Gleiter CH; Mühlbauer B; Schulz RM; Nilsson E; Antonin KH; Bieck PR
    J Neural Transm Gen Sect; 1994; 95(3):241-5. PubMed ID: 7865179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor.
    Dyck LE
    Life Sci; 1989; 44(17):1149-56. PubMed ID: 2716465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo.
    Lamensdorf I; Youdim MB; Finberg JP
    J Neurochem; 1996 Oct; 67(4):1532-9. PubMed ID: 8858937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of monofluoromethyldopa (MFMD) on trace amine levels.
    Dyck LE
    Life Sci; 1987 Feb; 40(6):571-5. PubMed ID: 3807650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of neurochemical effects of the monoamine oxidase inhibitors phenelzine, moclobemide and brofaromine in the rat after short- and long-term administration.
    Urichuk LJ; Allison K; Holt A; Greenshaw AJ; Baker GB
    J Affect Disord; 2000 May; 58(2):135-44. PubMed ID: 10781703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lesion-induced reductions in trace amine accumulation: dependence on MAO inhibitor pretreatment.
    Nguyen TV; Juorio AV; Greenshaw AJ
    Brain Res Bull; 1989 Feb; 22(2):197-200. PubMed ID: 2495844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of protein denaturing reactions on retardation of the activity of rat liver mitochondrial monoamine oxidase by clorgyline and deprenyl].
    Severina IS
    Biokhimiia; 1983 Sep; 48(9):1513-21. PubMed ID: 6414536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Displacement of in vivo binding of [3H]brofaromine to rat intestinal monoamine oxidase A by orally administered tyramine.
    Waldmeier PC; Stöcklin K
    Eur J Pharmacol; 1992 Jun; 216(2):243-7. PubMed ID: 1397011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The advent of a new generation of monoamine oxidase inhibitor antidepressants: pharmacologic studies with moclobemide and brofaromine.
    Lavian G; Finberg JP; Youdim MB
    Clin Neuropharmacol; 1993; 16 Suppl 2():S1-7. PubMed ID: 8313392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers.
    Bieck PR; Firkusny L; Schick C; Antonin KH; Nilsson E; Schulz R; Schwenk M; Wollmann H
    Clin Pharmacol Ther; 1989 Mar; 45(3):260-9. PubMed ID: 2920501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.
    Waldmeier PC
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Mar; 17(2):183-98. PubMed ID: 8430214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
    Green AR; Youdim MB
    Br J Pharmacol; 1975 Nov; 55(3):415-22. PubMed ID: 1203627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits.
    Weinstock M; Gorodetsky E; Wang RH; Gross A; Weinreb O; Youdim MB
    Neuropharmacology; 2002 Nov; 43(6):999-1005. PubMed ID: 12423669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical profiles of the novel reversible MAO-A inhibitors, moclobemide and brofaromine, in comparison with irreversible MAO inhibitors.
    Da Prada M; Kettler R; Keller HH; Burkard WP; Haefely WE
    J Neural Transm Suppl; 1989; 28():5-20. PubMed ID: 2677242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of monoamine oxidase inhibitors on the acid metabolites of some trace amines and of dopamine in the rat striatum.
    Dyck LE; Durden DA; Boulton AA
    Biochem Pharmacol; 1993 Mar; 45(6):1317-22. PubMed ID: 8466551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regional action of brofaromine on rat brain MAO-A and MAO-B.
    Gerardy J; Dresse A
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1141-55. PubMed ID: 9829294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tranylcypromine on the concentration of some trace amines in the diencephalon and hippocampus of the rat.
    Philips SR; Baker GB; McKim HR
    Experientia; 1980 Feb; 36(2):241-2. PubMed ID: 7371771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum.
    Schoepp DD; Azzaro AJ
    J Neurochem; 1981 Jun; 36(6):2025-31. PubMed ID: 6787175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.